Skip to main content
SNY
NASDAQ Life Sciences

CHMP 推荐欧盟批准 Sanofi 的创新性 Sarclisa 穿戴式注射器用于治疗多发性骨髓瘤

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$47.374
Mkt Cap
$112.64B
52W Low
$43.32
52W High
$55.995
Market data snapshot near publication time

summarizeSummary

Sanofi 的 Sarclisa 皮下制剂通过穿戴式注射器给药，已获得 CHMP 的欧盟批准积极推荐，用于治疗多发性骨髓瘤。该推荐基于研究结果，表明其疗效、药代动力学和安全性与静脉注射制剂相比具有可比性。如果获得批准，这将标志着一个重大进展，因为 Sarclisa 将成为首个通过穿戴式注射器递送的抗癌治疗，并且是欧盟中唯一提供穿戴式注射器和手动皮下注射两种选择的多发性骨髓瘤 anti-CD38 单克隆抗体。这一发展对 Sanofi 具有高度积极意义，因为它提高了患者的便捷性，并可能显著提高 Sarclisa 的竞争地位和市场渗透率。预计欧洲委员会将在未来几个月内做出最终决定。

在该公告发布时，SNY的交易价格为$47.37，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1126.4亿。 52周交易区间为$43.32至$56.00。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed SNY - Latest Insights

SNY
Apr 29, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
7
Sanofi Prices €2.3 Billion Multi-Tranche Bond Issue for General Corporate Purposes
Sentiment: Neutral
View Wiseek Article
SNY
Apr 27, 2026, 12:58 PM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Secures Key FDA Approvals for Dupixent and Tzield, Despite Sarclisa Delay
Sentiment: Positive
View Wiseek Article
SNY
Apr 24, 2026, 6:09 AM EDT
Source: GlobeNewswire
Importance Score:
8
EU Regulators Recommend Sanofi's Cenrifki for Secondary Progressive MS Approval
Sentiment: Positive
View Wiseek Article
SNY
Apr 23, 2026, 7:20 AM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Reports Strong Q1 Double-Digit Sales & EPS Growth, Multiple Regulatory Approvals, and Pipeline Advancements
Sentiment: Positive
View Wiseek Article
SNY
Apr 18, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Sanofi's Nuvaxovid COVID-19 Vaccine Shows Superior Tolerability in Head-to-Head Study
Sentiment: Positive
View Wiseek Article
SNY
Apr 15, 2026, 6:57 AM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Reports Positive Phase 2 Lunsekimig Data and EU Approval for Dupixent in Young Children with CSU
Sentiment: Positive
View Wiseek Article
SNY
Apr 07, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Sanofi's Lunsekimig Meets Phase 2 Endpoints in Asthma and CRSwNP, Bolstering Respiratory Pipeline
Sentiment: Positive
View Wiseek Article
SNY
Mar 31, 2026, 12:19 PM EDT
Filing Type: 6-K
Importance Score:
7
Sanofi Reports Positive Phase 3 Amlitelimab Data for Atopic Dermatitis, Advances Pipeline
Sentiment: Positive
View Wiseek Article
SNY
Mar 31, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Sanofi's Rezurock Secures EU Conditional Approval for Chronic Graft-vs-Host Disease
Sentiment: Positive
View Wiseek Article
SNY
Mar 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
CHMP Recommends EU Approval for Sanofi's Innovative Sarclisa On-Body Injector for Multiple Myeloma
Sentiment: Positive
View Wiseek Article